Summary
-
1.
The pharmacological properties of two selective inhibitors of monoamine oxidase (MAO) type B,l-deprenyl and MDL 72145 [(E)-2-(3,4-dimethyoxyphenyl)-3-fluoroallylamine, HCl], have been investigated in rats and mice in relation to their effects on MAO.
-
2.
Selective inhibition of MAO B achieved following 18 h pretreatment withl-deprenyl and/or MDL 72145 did not per se lead to prominent pharmacological activity; no effects were seen in the mouse “Behavioural Despair” test, hypothermia induced by reserpine in mice was neither prevented nor reversed and there was no change in the cardiovascular responsiveness of the pithed rat to tyramine, noradrenaline or stimulation of the spinal sympathetic outflow.
-
3.
l-Deprenyl differed from MDL 72145 in that short term treatment with this drug caused positive effects in the “Behavioural Despair” test, reversal of reserpine hypothermia, indirect sympathomimetic stimulation of blood pressure and heart rate in the pithed rat and ipsilateral rotation in rats with unilateral nigro-striatal lesions. Qualitatively similar effects were seen with dexamphetamine.
-
4.
The marked difference between the pharmacological effects of MDL 72145 andl-deprenyl despite equivalent inhibition of MAO B suggests that many of the pharmacological actions ofl-deprenyl result from its amphetaminelike sympathomimetic properties. MDL 72145 can, therefore, be considered a more reliable tool with which to explore the functional importance of MAO B inhibition in experimental animals and man.
Similar content being viewed by others
References
Bey P, Fozard J, Lacoste JM, McDonald JA, Zreika M, Palfreyman MG (1984a) (E)-2-3,4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase. J Med Chem 27:9–10
Bey P, Fozard J, McDonald IA, Palfreyman MG, Zreika M (1984b) MDL 72145: a potent and selective inhibitor of MAO type B. Br J Pharmacol 81:50P
Blackwell B (1981) Adverse effects of antidepressant drugs. Part I: Monoamine oxidase inhibitors and tricyclics. Drugs 21:201–219
Birkmayer W, Riederer P, Youdim MBH (1982) (−)Deprenyl in the treatment of Parkinson's Disease. Clin Neuropharmacology 5:195–230
Caramona MM (1982) Monoamine oxidase of types A and B in the saphenous vein and mesenteric artery of the dog. Naunyn-Schmiedeberg's Arch Pharmacol 319:121–124
Denes B, Greef K (1984) Investigations on the mechanism of positive inotropic action of (+)-tranylcypromine in isolated guineapig atria. Arzneimittelforschung 34:266–270
Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuadradit P, Shaw KM, Stern GM, Kumar P (1978) Deprenyl administration in man: a selective monoamine oxidase inhibitor without the cheese effect. Psychopharmacology 57:33–38
Elsworth JD, Sandler M, Lees AJ, Ward C, Stern GM (1982) The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties. J Neural Transm 54:105–110
Finberg JPM, Tenne M (1982) Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br J Pharmacol 77:13–21
Fowler CJ (1982) Selective inhibitors of monoamine oxidase types A and B and their clinical usefulness. Drugs of the Future 7:501–517
Fowler CJ, Ross SB (1984) Selective inhibitors of monoamine oxidase A and B: Biochemical, pharmacological and clinical properties. Med Res Rev 4:323–358
Fozard JR, Spedding M, Palfreyman MG, Wagner J, Möhring J, Koch-Weser J (1980) Depression of sympathetic nervous function bydl-α-monofluoromethyldopa, an enzyme-activated, irreversible inhibitor ofl-aromatic amino acid decarboxylase. J Cardiovasc Pharmacol 2:229–245
Fozard JR, Palfreyman MG, Zreika M (1984) The comparative pharmacology of two selective inhibitors of monoamine oxidase B: Deprenyl and MDL 72145. Br J Pharmacol 82:309P
Gillespie JS, Muir TC (1967) A method of stimulating the complete sympathetic outflow from spinal cord to the blood vessels in the pithed rat. Br J Pharmacol 30:78–87
Heikkila RE, Cabbat FS, Manzino L, Duvoisin RC (1981) Potentiation by deprenyl ofl-dopa induced circling in nigral-lesioned rats. Pharmac Biochem Behav 15:75–79
Jaffe JH (1980) Drug addition and drug abuse. In: Gilman AG, Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics, 6th edn. Macmillan, New York, pp 535–584
Jalfre M, Bucher B, Coston A, Mocquet G, Porsolt RD (1982) Neuropharmacological profile of MD 780515, a new reversible inhibitor of type A monoamine oxidase. Arch Int Pharmacodyn Ther 259:194–221
Johnston HA (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285–1297
Karoum F, Chuang L-W, Eisler TMS, Calnc DB, Leibowitz MR, Quitkin FR, Klein DF, Wyatt RJ (1982) Metabolism of (−)deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment. Neurology 32:503–509
Knoll J (1979) (−)Deprenyl — the MAO inhibitor without the “cheese effect”. Trends Neurol Sci 2:111–113
Knoll J (1983) Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 68 (Suppl 95): 57–80
Knoll J, Magyar K (1972) Some pharmacological effects of monoamine oxidase inhibitors. In: Coste E, Sandler M (eds) Monoamine oxidases — new vistas. Raven Press, New York pp 393–408
Koulu M, Lammintansta R (1981) Effects ofl-deprenyl on human growth hormone secretion. J Neural Transm 51:223–231
Lancet Editorial (1982) Deprenyl in Parkinson's Disease. Lancet (ii):695–696
Lavie P, Wajsbort J, Youdim MBH (1980) Deprenyl does not cause insomnia in parkinsonian patients. Comm Psychopharmacol 4:303–307
McDonald I, Lacoste JM, Bey P, Palfreyman MG, Zreika M (1985) Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships. J Med Chem 28:186–193
Neff NH, Goridis C (1972) Neuronal monoamine oxidase: specific enzyme types and their rate of formation. Adv Biochem Psychopharmacol 5:307–323
Palfreyman MG, Zreika M, McDonald I, Fozard JR, Bey P (1983) MDL 72145, an irreversible inhibitor of MAO B. L'encephale 9, Suppl 1:A3
Philips SR (1981) Amphetamine, p-hydroxyamphetamine and β-phenethylamine in mouse brain and urine after (−)- and (+)-deprenyl administration. J Pharmac Pharmacol 31:739–741
Porsolt RD, Bertin A, Jalfre M (1977) Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327–336
Porsolt RD, Pawelec C, Roux S, Jalfre M (1984) Discrimination of the amphetamine cue. Effects of A, B and mixed type inhibitors of monoamine oxidase. Neuropharmacol 23:569–573
Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6:542–544
Riederer P, Reynolds GP, Jellinger K (1984) The pharmacology of Parkinson's disease:l-dopa and beyond. Trends Pharmacol Sci 5:25–27
Robin M, Forler C, Palfreyman MG (1985) Effect of chronic apomorphine on the development of denervation supersensitivity. Pharmacol Biochem Behav 22:547–551
Simpson LL (1978) Evidence that deprenyl, a type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine. Biochem Pharmacol 27:1591–1595
Thornton C, Dore CJ, Elsworth JD, Herbert M, Stern GM (1980) The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmacol 70:163–166
Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system in the rat brain. Acta Physiol Scand (Suppl) 367:69–93
Zreika M, McDonald IA, Bey P, Palfreyman MG (1984) MDL 72145, an enzyme-activated irreversible inhibitor with selectivity for monoamine oxidase type B. J Neurochem 43:448–454
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fozard, J.R., Zreika, M., Robin, M. et al. The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties ofl-deprenyl and MDL 72145. Naunyn-Schmiedeberg's Arch. Pharmacol. 331, 186–193 (1985). https://doi.org/10.1007/BF00634237
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00634237